The dynamics of the Amyotrophic Lateral Sclerosis market are expected to change in the coming years as a result of advancements in diagnosis methodologies and increased disease awareness

December 17 19:00 2021
The dynamics of the Amyotrophic Lateral Sclerosis market are expected to change in the coming years as a result of advancements in diagnosis methodologies and increased disease awareness
Amyotrophic Lateral Sclerosis Market
The upcoming ALS therapies such as NurOwn, Arimoclomol, Ibudilast, and others are expected to address the current unmet needs of ALS patients

DelveInsight’s Amyotrophic Lateral Sclerosis market report thoroughly explains the Amyotrophic Lateral Sclerosis, historical and forecasted epidemiology, as well as the Amyotrophic Lateral Sclerosis market trends in the 7MM. 

Some of the Key Highlights from the Amyotrophic Lateral Sclerosis Market Report

  • As per DelveInsight estimates, the Amyotrophic Lateral Sclerosis prevalent population was 71,628 in the 7MM in 2020. 
  • In the US, Amyotrophic Lateral Sclerosis diagnosed cases were over 18 thousand in 2020.
  • According to age-specific data on ALS, it is more common in people aged 60–69. In the United States, the age group 60–69 had the highest number of ALS cases in 2020.
  • Leading companies in the ALS market include Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Amylyx, and others.
  • Key ALS therapies in the pipeline include NurOwn, Arimoclomol, Ibudilast, Tofersen, Verdiperstat, AMX0035, and others.

Have queries? Request for the sample @ Amyotrophic Lateral Sclerosis Market Outlook

Amyotrophic Lateral Sclerosis: Overview

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare neurological disease that primarily affects the nerve cells (neurons) that control voluntary muscle movement. Voluntary muscles are responsible for activities such as chewing, walking, and talking. The disease is progressive, which means that the symptoms worsen over time. 

Amyotrophic Lateral Sclerosis Epidemiology Segmentation

The Amyotrophic Lateral Sclerosis report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Amyotrophic Lateral Sclerosis Prevalent Population
  • Amyotrophic Lateral Sclerosis Diagnosed Prevalent Population 
  • Amyotrophic Lateral Sclerosis Gender-Specific Distribution
  • Amyotrophic Lateral Sclerosis Mutation-Specific Distribution
  • Amyotrophic Lateral Sclerosis Type-Specific Distribution
  • Amyotrophic Lateral Sclerosis Site of Onset
  • Amyotrophic Lateral Sclerosis Age-Specific Distribution

Amyotrophic Lateral Sclerosis Treatment Landscape

The major ALS treatment options include:

  • Physical Therapy, speech therapy, occupational therapy, breathing support
  • Drugs (Rilutek, Tiglutek, Raicava, Nuedexta, Exservan)
  • Supportive treatments

Amyotrophic Lateral Sclerosis Market Outlook 

According to estimates, the largest ALS market size was found in the United States, while the smallest was found in Spain across the 7MM. Furthermore, the upcoming ALS therapies such as NurOwn, Arimoclomol, Ibudilast, and others are expected to address the current unmet needs of ALS patients while also contributing to the overall growth of the ALS market size.

  • Amyotrophic Lateral Sclerosis Pipeline Therapies and Key Companies 
  • NurOwn: Brainstorm-Cell Therapeutics
  • Arimoclomol: Orphazyme
  • Ibudilast: MediciNova
  • Tofersen: Biogen
  • Verdiperstat: Biohaven Pharmaceutical
  • AMX0035: Amylyx

Learn more about the emerging therapies and companies @ ALS Pipeline Therapies 

Table of Contents

1.

Key Insights

2.

Executive Summary

3.

Amyotrophic Lateral Sclerosis (ALS) Market Overview at a Glance

4.

Disease Background and Overview: Amyotrophic Lateral Sclerosis (ALS)

5.

European Federation of Neurological Societies (EFNS) guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) (2012)

6.

Recognized Establishments

7.

Treatment and Management of ALS

8.

American Association of Neurology (AAN) Guidelines for Care and Management of patients with ALS (2009)

9.

Management Algorithm for Respiratory Dysfunction in ALS

10.

Management guidelines for ALS in Japan, the United States, and Europe

11.

Epidemiology and Patient Population

12.

Country Wise-Epidemiology of Amyotrophic Lateral Sclerosis

13.

Unmet Needs

14.

Marketed Drugs

15.

Emerging Drugs

16.

Market Access and Reimbursement

17.

Amyotrophic Lateral Sclerosis (ALS): Seven Major Market Analysis

18.

7MM Market Outlook

19.

Case Reports

20.

Market Drivers

21.

Market Barriers

22.

SWOT Analysis

23.

Appendix

24.

DelveInsight Capabilities

25.

Disclaimer

26.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Amyloidosis Market

DelveInsight’s “Amyloidosis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology, as well as the Amyloidosis market trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/